Hemispherx BioPharma Inc (AMEX: HEB) surged up 4.86% to $0.279 on a
traded volume of 761k shares. The Rosen Law Firm reminds investors of
the important February 22, 2013 lead plaintiff deadline in the class
action filed on behalf of investors who purchased the securities of
Hemispherx Biopharma Inc from March 19, 2012 through December 17, 2012.
Hemispherx Biopharma is a specialty pharmaceutical company engaged in
the clinical development of new drugs therapies based on natural immune
system enhancing technologies for the treatment of viral and immune
based chronic disorders.
Last updated 4 Aug 11 Course Title: OWASP Top 10 Threats and Mitigation Exam Questions - Single Select 1) Which of the following consequences is most likely to occur due to an injection attack? Spoofing Cross-site request forgery Denial of service Correct Insecure direct object references 2) Your application is created using a language that does not support a clear distinction between code and data. Which vulnerability is most likely to occur in your application? Injection Correct Insecure direct object references Failure to restrict URL access Insufficient transport layer protection 3) Which of the following scenarios is most likely to cause an injection attack? Unvalidated input is embedded in an instruction stream. Correct Unvalidated input can be distinguished from valid instructions. A Web application does not validate a client’s access to a resource. A Web action performs an operation on behalf of the user without checkin...
ReplyDeleteHemispherx BioPharma, Inc. (NYSE: HEB) shares rallied over 17 percent on almost double the average daily volume Wednesday. The Prescription Drug User Fee Act review goal for the FDA to complete its review of the NDA for Ampligen is February 2, 2013.